While they may sound similar, these two approaches are quite different, especially in terms of invasiveness, cost, recovery, and results
Individuals already taking GLP-1 receptor agonists for diabetes or weight management should continue their prescribed therapy as directed, but should not expect guaranteed cognitive benefits beyond those associated with improved metabolic health
GLP-1 Therapy Alone: Why It May Be More Effective Long-Term Clinical trials show that GLP-1 receptor agonists like semaglutide achieve meaningful, sustained weight loss on their own without the cardiovascular burden of sympathomimetic drugs
Retatrutide is an investigational compound not approved by the FDA for any indication
According to Cure's January 2025 patient survey white paper, side effects from taking GLP-1s were common but typically manageable